BISANTHRAPYRAZOLES AS ANTI-CANCER AGENTS

摘要

Disclosed are novel bisanthrapyrazoles that likely act as bisintercalators and topoisomerase Ila inhibitors. These compounds show potent inhibition of cancer cell growth, and certain bisanthrapyrazoles bind to DNA more tightly than doxorubicin, a known intercalating anti-cancer drug. Molecular modeling techniques are also disclosed that allow one to predict the DNA binding strength of various intercalators.